IN2012DN06436A - - Google Patents
Info
- Publication number
- IN2012DN06436A IN2012DN06436A IN6436DEN2012A IN2012DN06436A IN 2012DN06436 A IN2012DN06436 A IN 2012DN06436A IN 6436DEN2012 A IN6436DEN2012 A IN 6436DEN2012A IN 2012DN06436 A IN2012DN06436 A IN 2012DN06436A
- Authority
- IN
- India
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- piperazine
- pharmaceutically
- dioxoethyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 abstract 2
- QRPZBKAMSFHVRW-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione Chemical compound C1=2NC=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 QRPZBKAMSFHVRW-UHFFFAOYSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 abstract 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960002656 didanosine Drugs 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000366 emtricitabine Drugs 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 piperazine compound Chemical class 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- 229960000523 zalcitabine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55576704P | 2004-03-24 | 2004-03-24 | |
| PCT/US2005/006277 WO2005102392A2 (en) | 2004-03-24 | 2005-03-01 | Combinations for treating hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN06436A true IN2012DN06436A (enExample) | 2015-10-09 |
Family
ID=34961940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6436DEN2012 IN2012DN06436A (enExample) | 2004-03-24 | 2005-03-01 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7776863B2 (enExample) |
| EP (1) | EP1732604B1 (enExample) |
| JP (1) | JP4847441B2 (enExample) |
| KR (1) | KR101158140B1 (enExample) |
| CN (1) | CN1956720B (enExample) |
| AR (1) | AR048333A1 (enExample) |
| AT (1) | ATE474602T1 (enExample) |
| AU (1) | AU2005235116B2 (enExample) |
| BR (1) | BRPI0509140A (enExample) |
| CA (1) | CA2561146C (enExample) |
| CY (1) | CY1111613T1 (enExample) |
| DE (1) | DE602005022420D1 (enExample) |
| DK (1) | DK1732604T3 (enExample) |
| ES (1) | ES2347801T3 (enExample) |
| GE (1) | GEP20104925B (enExample) |
| HR (1) | HRP20100434T1 (enExample) |
| IL (1) | IL178141A (enExample) |
| IN (1) | IN2012DN06436A (enExample) |
| MY (1) | MY144318A (enExample) |
| NO (1) | NO337116B1 (enExample) |
| NZ (1) | NZ549778A (enExample) |
| PE (1) | PE20060148A1 (enExample) |
| PL (1) | PL1732604T3 (enExample) |
| PT (1) | PT1732604E (enExample) |
| RU (1) | RU2367439C2 (enExample) |
| SI (1) | SI1732604T1 (enExample) |
| TW (1) | TWI347184B (enExample) |
| UA (1) | UA88463C2 (enExample) |
| WO (1) | WO2005102392A2 (enExample) |
| ZA (1) | ZA200607959B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US7501419B2 (en) * | 2006-04-25 | 2009-03-10 | Bristol-Myers Squibb Company | 4-Squarylpiperazine derivatives as antiviral agents |
| US7572810B2 (en) * | 2006-06-08 | 2009-08-11 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
| US7504399B2 (en) | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
| JP5433691B2 (ja) * | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体 |
| EP2303876B1 (en) * | 2008-06-25 | 2014-03-19 | Bristol-Myers Squibb Company | Diketo azolopiperidines and azolopiperazines as anti-hiv agents |
| US20110295365A1 (en) * | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| EP2601174B1 (en) | 2010-08-06 | 2014-11-26 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| US8912195B2 (en) | 2010-12-02 | 2014-12-16 | Bristol-Myers Squibb Company | Alkyl amides as HIV attachment inhibitors |
| PT2670751E (pt) | 2011-01-31 | 2015-07-29 | Bristol Myers Squibb Co | Métodos de fabrico de um composto profármaco inibidor da fixação do vih e intermediários |
| WO2012142080A1 (en) | 2011-04-12 | 2012-10-18 | Bristol-Myers Squibb Company | Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors |
| EP2751119B1 (en) | 2011-08-29 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| WO2013033059A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| US9193725B2 (en) | 2012-03-14 | 2015-11-24 | Bristol-Meyers Squibb Company | Cyclic hydrazine derivatives as HIV attachment inhibitors |
| WO2014025854A1 (en) | 2012-08-09 | 2014-02-13 | Bristol-Myers Squibb Company | Piperidine amide derivatives as hiv attachment inhibitors |
| ES2616432T3 (es) | 2012-08-09 | 2017-06-13 | VIIV Healthcare UK (No.5) Limited | Derivados de alquenos tricíclicos como inhibidores de la unión del VIH |
| US9586957B2 (en) * | 2013-03-27 | 2017-03-07 | VIIV Healthcare UK (No.5) Limited | 2-keto amide derivatives as HIV attachment inhibitors |
| WO2016210130A1 (en) * | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| WO2023172635A1 (en) * | 2022-03-08 | 2023-09-14 | Emory University | Predictive model for variants associated with drug resistance and theranostic applications thereof |
| US12425371B2 (en) * | 2022-09-16 | 2025-09-23 | Cisco Technology, Inc. | System and method for providing SCHC-based edge firewalling |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ506623A (en) * | 1998-03-02 | 2002-10-25 | Univ North Carolina | Acylated betulin and dihydrobetulin derivatives, preparation thereof and use in treatment of retroviral infections |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| RU2192870C1 (ru) * | 2001-07-02 | 2002-11-20 | Закрытое акционерное общество "Агрофарм ПитерСиб" | Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией |
| CA2469592C (en) * | 2001-12-12 | 2005-08-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| CA2467718C (en) * | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
-
2005
- 2005-02-24 US US11/064,683 patent/US7776863B2/en active Active
- 2005-03-01 UA UAA200611163A patent/UA88463C2/ru unknown
- 2005-03-01 DK DK05723932.9T patent/DK1732604T3/da active
- 2005-03-01 CA CA2561146A patent/CA2561146C/en not_active Expired - Lifetime
- 2005-03-01 AT AT05723932T patent/ATE474602T1/de active
- 2005-03-01 WO PCT/US2005/006277 patent/WO2005102392A2/en not_active Ceased
- 2005-03-01 ES ES05723932T patent/ES2347801T3/es not_active Expired - Lifetime
- 2005-03-01 GE GEAP20059667A patent/GEP20104925B/en unknown
- 2005-03-01 IN IN6436DEN2012 patent/IN2012DN06436A/en unknown
- 2005-03-01 CN CN2005800160669A patent/CN1956720B/zh not_active Expired - Lifetime
- 2005-03-01 HR HR20100434T patent/HRP20100434T1/hr unknown
- 2005-03-01 KR KR1020067019595A patent/KR101158140B1/ko not_active Expired - Lifetime
- 2005-03-01 JP JP2007504971A patent/JP4847441B2/ja not_active Expired - Lifetime
- 2005-03-01 NZ NZ549778A patent/NZ549778A/en not_active IP Right Cessation
- 2005-03-01 BR BRPI0509140-3A patent/BRPI0509140A/pt not_active Application Discontinuation
- 2005-03-01 PL PL05723932T patent/PL1732604T3/pl unknown
- 2005-03-01 RU RU2006137555/14A patent/RU2367439C2/ru active
- 2005-03-01 EP EP05723932A patent/EP1732604B1/en not_active Expired - Lifetime
- 2005-03-01 PT PT05723932T patent/PT1732604E/pt unknown
- 2005-03-01 SI SI200531100T patent/SI1732604T1/sl unknown
- 2005-03-01 AU AU2005235116A patent/AU2005235116B2/en not_active Expired
- 2005-03-01 DE DE602005022420T patent/DE602005022420D1/de not_active Expired - Lifetime
- 2005-03-17 MY MYPI20051136A patent/MY144318A/en unknown
- 2005-03-18 TW TW094108462A patent/TWI347184B/zh not_active IP Right Cessation
- 2005-03-23 AR ARP050101159A patent/AR048333A1/es not_active Application Discontinuation
- 2005-03-28 PE PE2005000344A patent/PE20060148A1/es not_active Application Discontinuation
-
2006
- 2006-09-17 IL IL178141A patent/IL178141A/en active IP Right Review Request
- 2006-09-22 ZA ZA200607959A patent/ZA200607959B/en unknown
- 2006-10-06 NO NO20064547A patent/NO337116B1/no unknown
-
2010
- 2010-10-20 CY CY20101100937T patent/CY1111613T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20104925B (en) | Combinations for treating hiv infection | |
| WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
| NZ627824A (en) | Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide | |
| TW200621762A (en) | Novel compounds | |
| GB0112348D0 (en) | Compounds | |
| MXPA04006553A (es) | Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih. | |
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| MX2007003321A (es) | Derivados heterociclicos y su uso como agentes terapeuticos. | |
| MY132106A (en) | New pyridazin-3(2h)-one derivatives | |
| SE0202463D0 (sv) | Novel compounds | |
| AP2002002455A0 (en) | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. | |
| WO2008142055A3 (en) | Antiviral agents | |
| WO2006086447A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
| GB0114286D0 (en) | Nucleoside Derivatives | |
| WO2006034341A3 (en) | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase | |
| MXPA05001581A (es) | Algunas imidazopiridinas novedosas y su uso. | |
| CA2322900A1 (en) | 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors | |
| EA200601654A1 (ru) | Ингибиторы интегразы вич | |
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| EP2033954A4 (en) | COMPOUND 6- (4-OXOQUINOLIN-SUBSTITUTED BENZYL) AND USE THEREOF AS INHIBITOR OF HIV INTEGRASE | |
| GB0106661D0 (en) | Pharmaceutically active compounds | |
| CA2668320A1 (en) | Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction | |
| UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
| MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. |